Age-Dependent Systemic Regulation of C1q/TNF-Related Protein 3 and Progranulin in Patients with Cystic Fibrosis: Biomarkers or Therapeutic Targets?

囊性纤维化患者中 C1q/TNF 相关蛋白 3 和前粒蛋白的年龄依赖性系统调节:生物标志物还是治疗靶点?

阅读:1

Abstract

Background/Objectives: C1q/TNF-related protein 3 (CTRP3), progranulin (PGRN), and chemerin are adipokines that participate in systemic inflammation. This study systematically examined adipokine levels in cystic fibrosis patients of different ages to evaluate their role in inflammatory, metabolic, and hepatic processes. Thirty-seven pediatric and thirty-three adult CF patients were enrolled to assess the potential of these adipokines as biomarkers. Methods: Anthropometric and physiological data, pulmonary function (forced expiratory volume, FEV1; vital capacity, VC), and liver fibrosis score FIB-4 were assessed. Liver stiffness was measured by transient elastography. Serum samples from 40 healthy adult volunteers served as the control group. Serum concentrations of chemerin, CTRP3, and PGRN were quantified by enzyme-linked immunosorbent assay (ELISA). Results: Compared with healthy controls, adults with CF had markedly lower circulating CTRP3 levels, whereas PGRN concentrations were significantly higher. Among CF patients, both CTRP3 and PGRN were higher in the pediatric group than in adults, while chemerin did not vary with age. The presence of cystic fibrosis-related liver disease (CFLD) did not significantly alter adipokine levels relative to CF patients without liver disease. Receiver operator characteristic (ROC) analysis showed that circulating PGRN could reliably differentiate CF patients from controls; none of the three adipokines predicted the presence of CFLD. CTRP3 and PGRN were inversely correlated with age, BMI, and pulmonary function. Conclusions: Overall, our data support systemic PGRN as a potential biomarker for CF and indicate an age-dependent regulation of circulating CTRP3 and PGRN. Both proteins were inversely associated with BMI, inflammatory markers, liver fibrosis, and pulmonary capacity.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。